Samantha Aberton
Nurse Practitioner · Salt Lake City, UTNPI 1518538842
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,064 of the $9,798 with a category attached, or 72.1%. It is spread thinly across 33 manufacturers, the largest accounting for just 15.2%. 2025 is the largest year on record at $3,982, more than ten times the $160 reported in 2021. Among nurse practitioner clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 310 payments — averaging $31.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- Cvrx, Inc.$1K
- Impulse Dynamics (USA) Inc.$1K
- E.r. Squibb & Sons, L.L.C.$1K
- Actelion Pharmaceuticals US, Inc.$732
- Medtronic$582
- plus $3K from 27 others
What the payments were for
- Travel & lodging$2,52526%
- Food & beverage$7,06472%
- Education$2092%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 23 | $1,486 |
| Cvrx, Inc. | 8 | $1,282 |
| Impulse Dynamics (USA) Inc. | 8 | $1,178 |
| E.r. Squibb & Sons, L.L.C. | 59 | $1,080 |
| Actelion Pharmaceuticals US, Inc. | 33 | $732 |
| Medtronic | 24 | $582 |
| Pfizer | 20 | $362 |
| Abbott | 4 | $320 |
| Bayer | 15 | $319 |
| Johnson & Johnson | 15 | $284 |
| Novartis | 14 | $283 |
| Amgen | 11 | $204 |
| Boston Scientific | 10 | $176 |
| Philips North America LLC | 7 | $169 |
| Edwards Lifesciences | 1 | $149 |
| Merck | 7 | $145 |
| Boehringer Ingelheim | 7 | $136 |
| Kiniksa Pharmaceuticals, Ltd. | 6 | $133 |
| Lexicon Pharmaceuticals, Inc. | 5 | $108 |
| Daiichi Sankyo Inc. | 6 | $97 |
| Bridgebio Pharma, Inc. | 3 | $97 |
| Alnylam Pharmaceuticals Inc. | 3 | $84 |
| AstraZeneca | 5 | $69 |
| Scpharmaceuticals Inc. | 3 | $55 |
| Baxter Healthcare | 2 | $52 |
| Inspire Medical Systems, Inc. | 2 | $49 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $29 |
| Heartflow, Inc. | 1 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $22 |
| Ionis Pharmaceuticals, Inc. | 1 | $18 |
| Recor Medical Inc | 1 | $17 |
| Cardiva Medical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$1,821
- Barostim Neo System$1,093
- Impella$582
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$157
- CARDIOMEMS$128
- CAMZYOS$125
How this compares
$9,798 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 11 | $447,735 |
| CamzyosMavacamten | 45 | $368,207 |
| EliquisApixaban | 124 | $156,945 |
| EntrestoSacubitril/Valsartan | 86 | $98,648 |
| FarxigaDapagliflozin Propanediol | 88 | $83,570 |
| XareltoRivaroxaban | 17 | $25,172 |
| Repatha SureclickEvolocumab | 17 | $8,791 |
| Midodrine Hcl | 42 | $3,559 |
| Metoprolol Succinate | 156 | $1,584 |
| Atorvastatin Calcium | 184 | $1,532 |
| Bisoprolol Fumarate | 55 | $1,311 |
| Spironolactone | 203 | $1,264 |
| Potassium Chloride | 82 | $1,259 |
| Amiodarone Hcl | 66 | $1,148 |
| Ezetimibe | 35 | $998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $362 | $604,681135 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $1,080 | $368,20745 claims |
| NovartisEntresto | $283 | $98,64886 claims |
| AstraZenecaFarxiga | $69 | $83,57088 claims |
| Johnson & JohnsonXarelto | $284 | $25,17217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Salt Lake City
- Julia BattenSalt Lake City$223K
- Merin KinikiniSalt Lake City$19K
- Phillip BowmanSalt Lake City$13K
- Dana ShawSalt Lake City$10K
- Jennifer BushSalt Lake City$7K
- Stacy ParrySalt Lake City$6K
- Krystal BischoffSalt Lake City$5K
- Jennifer UrchSalt Lake City$5K
- Millie DorseySalt Lake City$5K
- Diane RussellSalt Lake City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.